A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population
Jeanine Flanigan(Sanden (Japan)), G.H. Lyman(Duke University), Marion Schauf, MICHAEL TINDAL(Sanden (Japan)), Stephen Chaplin(Vencore (United States)), Edward Li(Sanden (Japan)), Andrea Gundlach(Macula Vision Research Foundation), Joris van Stiphout(Vencore (United States))
Cited by 1
Related Papers
Synergistic Function of E2F7 and E2F8 Is Essential for Cell Survival and Embryonic Development
|Developmental Cell|2008|231
Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death
|The Journal of Cell Biology|2017|175
Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database
|BMC Public Health|2018|85
Projecting future drug expenditures—2012
|American Journal of Health-System Pharmacy|2012|81